Breaking News Bar

Business News and Information

Recent Quotes
My Watchlist
Indicators
Local Stocks
The Daily Herald Market Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

76.40 USD UNCHANGED
Streaming Delayed Price Updated: 5:12 AM EDT, Apr 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
80 81 Next >
Merck Announces Week 96 Data from Phase 2b Study Evaluating Islatravir in Combination With Doravirine in Adults With HIV-1 Infection
Merck Announces Week 96 Data from Phase 2b Study Evaluating Islatravir in Combination with Doravirine in Adults with HIV-1 Infection 
From Business Wire News Releases
Merck Announces Retirement of Dr. Roger M. Perlmutter; Dr. Dean Y. Li Appointed as President, Merck Research Laboratories
Merck Announces Retirement of Dr. Roger M. Perlmutter; Dr. Dean Y. Li Appointed as President, Merck Research Laboratories 
From Business Wire News Releases
Global Brain Tumor Therapeutics Market Projected to Exceed $2.70 Billion By 2023
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Global Brain Tumor Therapeutics Market Projected to Exceed $2.70 Billion By 2023
Financialnewsmedia.com News Commentary 
From PR Newswire
Merck to Present New Data from the Company’s Diverse HIV Portfolio and Pipeline at HIV Glasgow 2020
Merck to Present New Data from the Company’s Diverse HIV Portfolio and Pipeline at HIV Glasgow 2020 
From Business Wire News Releases
Merck to Hold Third-Quarter 2020 Sales and Earnings Conference Call on October 27
Merck to Hold Third-Quarter 2020 Sales and Earnings Conference Call on October 27 
From Business Wire News Releases
Merck Animal Health Supports Rabies Elimination by 2030 on World Rabies Day
Merck Animal Health Supports Rabies Elimination by 2030 on World Rabies Day 
From Business Wire News Releases
Merck Joins Groundbreaking Gender and Diversity KPI Alliance
Tags Partnerships Merck & Co/ KPI Alliance
From 3BL Media: Corporate Social Responsibility, Energy and Health News
NEXPLANON® Contraceptive Arm Implant Now Available for Use in Canada
From PR Newswire
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Esophageal Cancer
KEYTRUDA Plus Chemotherapy Reduced Risk of Death by 27% Vs Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Esophageal Cancer 
From Business Wire News Releases
First-Line Treatment With Merck’s KEYTRUDA® (pembrolizumab) Doubled Five-Year Survival Rate (31.9%) Versus Chemotherapy (16.3%) in Certain Patients With Metastatic Non-Small Cell Lung Cancer Whose Tum
First-Line Treatment With Merck’s KEYTRUDA Doubled Five-Year Survival Rate (31.9%) Versus Chemotherapy (16.3%) 
From Business Wire News Releases
LYNPARZA® (olaparib) Receives Positive Opinion from EU CHMP for Treatment of BRCA1/2 Metastatic Castration-Resistant Prostate Cancer (mCRPC)
LYNPARZA® (olaparib) Receives Positive Opinion from EU CHMP for Treatment of BRCA1/2 Metastatic Castration-Resistant Prostate Cancer (mCRPC) 
From Business Wire News Releases
LYNPARZA® (olaparib) Recommended for Approval in EU by CHMP as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer
LYNPARZA Recommended for Approval in EU by CHMP as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer 
From Business Wire News Releases
LYNPARZA® (olaparib) Reduced the Risk of Death by 31% in BRCA1/2 or ATM-mutated Metastatic Castration-Resistant Prostate Cancer in Phase III Profound Trial
AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced final results from the Phase III PROfound trial that showed LYNPARZA (olaparib) demonstrated a... 
From Business Wire News Releases
LYNPARZA Reduced Risk of Death by 31% vs. Enzalutamide or Abiraterone for Men with BRCA1/2 or ATM-Mutated Metastatic Castration Resistant Prostate Cancer Who Progressed Following Enzalutamide or Abira
LYNPARZA Reduced Risk of Death by 31% for Men with BRCA1/2 or ATM-Mutated mCRPC Who Progressed Following Enzalutamide or Abiraterone in Ph 3 Trial 
From Business Wire News Releases
Merck Presents Promising New Data for Three Investigational Medicines From Diverse and Expansive Oncology Pipeline at ESMO Virtual Congress 2020
Merck Presents Promising New Data for Three Investigational Medicines From Diverse and Expansive Oncology Pipeline at ESMO Virtual Congress 2020 
From Business Wire News Releases
Merck and Eisai Present First-Time Data From Two Studies Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020
Merck and Eisai Present First-Time Data From Two Studies Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Seven Different Tumor Types 
From Business Wire News Releases
Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Distant Metastasis or Death by 40% Versus Placebo as Adjuvant Treatment in Resected, High-Risk Stage III Melanoma
Merck’s KEYTRUDA Reduced the Risk of Distant Metastasis or Death by 40% Versus Placebo as Adjuvant Treatment in Resected, High-Risk Stage III Melanoma 
From Business Wire News Releases
LYNPARZA® (olaparib) Improved Median Progression-Free Survival to Over Four and a Half Years Compared to 13.8 Months with Placebo for Patients with BRCA-Mutated Advanced Ovarian Cancer
LYNPARZA® Improved Median Progression-Free Survival to Over Four and a Half Years for Patients with BRCA-Mutated Advanced Ovarian Cancer 
From Business Wire News Releases
Merck to Hold Investor Briefing Following ESMO Virtual Congress 2020
Merck to Hold Investor Briefing Following ESMO Virtual Congress 2020 
From Business Wire News Releases
BRENZYS® (etanercept injection) now indicated for the Treatment of Plaque Psoriasis, Psoriatic Arthritis and Juvenile Idiopathic Arthritis
From PR Newswire
Merck to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference
Merck to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference 
From Business Wire News Releases
Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations
Seattle Genetics, Inc. (Nasdaq: SGEN) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced two new strategic oncology collaborations. 
From Business Wire News Releases
Merck to Present at the Morgan Stanley 18th Annual Virtual Global Healthcare Conference
Merck to Present at the Morgan Stanley 18th Annual Virtual Global Healthcare Conference 
From Business Wire News Releases
Merck Announces Positive Topline Results from Two Phase 3 Adult Studies Evaluating V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine, Including Pivotal Trial
Merck Announces Positive Topline Results from Two Phase 3 Studies Evaluating V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine 
From Business Wire News Releases
Merck’s Gefapixant (45 mg Twice Daily) Significantly Decreased Cough Frequency Compared to Placebo at Week 12 and 24 in Patients with Refractory or Unexplained Chronic Cough
Merck’s Gefapixant Significantly Decreased Cough Frequency Compared to Placebo in Patients with Refractory or Unexplained Chronic Cough 
From Business Wire News Releases
Biopharma Leaders Unite to Stand With Science
The CEOs of AstraZeneca (LSE/STO/NYSE: AZN), BioNTech (NASDAQ: BNTX), GlaxoSmithKline plc (LSE/NYSE: GSK), Johnson & Johnson (NYSE: JNJ), Merck (NYSE: MRK), known as MSD outside the United States and... 
From Business Wire News Releases
Biopharma Leaders Unite to Stand with Science
From GlobeNewswire News Releases
Biopharma Leaders Unite To Stand With Science
Biopharma leaders unite to stand with science. 
From Business Wire News Releases
Biopharma Leaders Unite to Stand with Science
The CEOs of AstraZeneca (LSE/STO/NYSE: AZN), BioNTech (NASDAQ: BNTX), GlaxoSmithKline plc (LSE/NYSE: GSK), Johnson & Johnson (NYSE: JNJ), Merck (NYSE: MRK), known as MSD outside the United States and... 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
80 81 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
bottom clear
Search DailyHerald.com for articles
More ways to search Daily Herald
Obituaries
Search DailyHerald.com obituaries. » Daily Herald newspaper archive
Find archived newspaper articles back to 1901. »
Digital Subscriptions
Activate Subscriber Access Purchase a Digital Subscription
Home Delivery
Start a New Subscription Manage Account